moclobemide


Also found in: Wikipedia.

moclobemide

A reversible mono-amine oxidase inhibitor (MAOI) used to manage depression and performance anxiety. It is not approved for use in the USA.
 
Adverse effects
Insomnia, headache, dizziness.

moclobemide

Aurorix®, Manerix® Neurology A mono-amine oxidase inhibitor used to manage depression

moclobemide

A reversible MONO-AMINE OXIDASE INHIBITOR drug used to treat severe depression and social phobia. A brand name is Manerix.
References in periodicals archive ?
In Taiwan, only one drug in this class (moclobemide) is approved.
[1, 27, 76, 78] In a prospective study carried out in Turkey investigating the efficacy and tolerability of moclobemide therapy in 21 FM patients, there was no significant improvement in symptoms other than pain and it was concluded that moclobemide could be used in patients with FM who had severe depression.
Additionally, MAO inhibitors, such as clorgiline, phenelzine, moclobemide and tranylcypromine, which are used to treat depression, and anticholinergics, such as scopolamine, biperidene, trihexyphenydil and benztropine, have some serious potential to increase mood and physical resistance, very similar to amphetamines.
Stefanis, "Clinical, endocrine and neurochemical effects of moclobemide in depressed patients," Acta Psychiatrica Scandinavica, vol.
The reagents used in the enzymatic assay including Ampliflu[TM] Red (10-acetyl-3,7-dihydroxyphenoxazine), peroxidase from horseradish, hMAO-A, hMAO-B, [H.sub.2][O.sub.2], tyramine hydrochloride, selegiline, and moclobemide were purchased from Sigma-Aldrich (Steinheim, Germany).
The first molecule with these properties was moclobemide, which, nevertheless, did not have the expected clinical success.
Standards of moclobemide and selegiline are used as positive controls for MAO-A and MAO-B inhibition, respectively.
MAO inhibitors including tranylcypromine, isocarboxazid, phenelzine, and moclobemide are often used as first-line therapy [7].
In recent years, the MAOI has been represented by moclobemide, which selectively reversibly inhibits type A MAO and has been attracting attention again due to its side effects.
The patient had been administered different medication regimens for the last 3 years and lamotrigine 100 mg/day and moclobemide 600 mg/day for the last 1.5 years.
Moreover, the novel selective and reversible MAOI (such as moclobemide) are reported to be both well-tolerated compounds and free from the above-mentioned interaction included in the elderly [47].
In terms of active principle, amitriptyline (34.7%) and imipramine (13.9%) were the most used among the TCAs, fluoxetine among SSRIs (18.1%) and moclobemide among the MAOIs (5.1%).